{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T17:54:32Z","timestamp":1793987672669,"version":"4.8.0"},"reference-count":154,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100021771","name":"Tabriz University of Medical Sciences Student Research Committee","doi-asserted-by":"publisher","award":["69650"],"award-info":[{"award-number":["69650"]}],"id":[{"id":"10.13039\/501100021771","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004366","name":"Tabriz University of Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004366","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.ejmech.2023.115182","type":"journal-article","created":{"date-parts":[[2023,2,4]],"date-time":"2023-02-04T11:14:18Z","timestamp":1675509258000},"page":"115182","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["S1PR1 modulators in multiple sclerosis: Efficacy, safety, comparison, and chemical structure insights"],"prefix":"10.1016","volume":"250","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0927-6156","authenticated-orcid":false,"given":"Omid Jamshidi","family":"Kandjani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6107-8141","authenticated-orcid":false,"given":"Shadi","family":"Yaqoubi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4831-6691","authenticated-orcid":false,"given":"Samad Shams","family":"Vahdati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9335-9973","authenticated-orcid":false,"given":"Behnam","family":"Borhannejad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9427-0770","authenticated-orcid":false,"given":"Siavoush","family":"Dastmalchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7781-4019","authenticated-orcid":false,"given":"Ali Akbar","family":"Alizadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2023.115182_bib1","first-page":"1816","article-title":"Rising prevalence of multiple sclerosis worldwide: insights from the Atlas of MS","volume":"26","author":"Walton","year":"2020"},{"key":"10.1016\/j.ejmech.2023.115182_bib2","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1212\/WNL.59.7.1006","article-title":"Early onset multiple sclerosis: a longitudinal study","volume":"59","author":"Boiko","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.ejmech.2023.115182_bib3","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0387-7604(03)00035-4","article-title":"Multiple sclerosis in children","volume":"25","author":"Gadoth","year":"2003","journal-title":"Brain Dev."},{"key":"10.1016\/j.ejmech.2023.115182_bib4","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.829331","article-title":"Late-onset MS: disease course and safety-efficacy of DMTS","volume":"13","author":"Buscarinu","year":"2022","journal-title":"Front. Neurol."},{"key":"10.1016\/j.ejmech.2023.115182_bib5","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1212\/WNL.0000000000000560","article-title":"Defining the clinical course of multiple sclerosis: the 2013 revisions","volume":"83","author":"Lublin","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.ejmech.2023.115182_bib6","first-page":"32","article-title":"A comparison of memory performance in relapsing-remitting, primary progressive and secondary progressive, multiple sclerosis","volume":"14","author":"Gaudino","year":"2001","journal-title":"Neuropsychiatry, neuropsychology, and behavioral neurology"},{"key":"10.1016\/j.ejmech.2023.115182_bib7","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1212\/01.WNL.0000129828.03714.90","article-title":"Differences in cognitive impairment of relapsing remitting, secondary, and primary progressive MS","volume":"63","author":"Huijbregts","year":"2004","journal-title":"Neurology"},{"issue":"Suppl 1","key":"10.1016\/j.ejmech.2023.115182_bib8","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00415-008-1002-8","article-title":"A shift from adaptive to innate immunity: a potential mechanism of disease progression in multiple sclerosis","volume":"255","author":"Weiner","year":"2008","journal-title":"J. Neurol."},{"key":"10.1016\/j.ejmech.2023.115182_bib9","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1016\/S0140-6736(08)61620-7","article-title":"Multiple sclerosis","volume":"372","author":"Compston","year":"2008","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.ejmech.2023.115182_bib10","series-title":"Harrison's Principles of Internal Medicine","author":"Kasper","year":"2015"},{"key":"10.1016\/j.ejmech.2023.115182_bib11","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1093\/brain\/awac016","article-title":"How patients with multiple sclerosis acquire disability","volume":"145","author":"Lublin","year":"2022","journal-title":"Brain: J. Neurol."},{"key":"10.1016\/j.ejmech.2023.115182_bib12","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a028936","article-title":"Multiple sclerosis pathology","volume":"8","author":"Lassmann","year":"2018","journal-title":"Cold Spring Harbor perspectives in medicine"},{"key":"10.1016\/j.ejmech.2023.115182_bib13","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1212\/01.CON.0000433291.23091.65","article-title":"Pathology of multiple sclerosis: where do we stand?","volume":"19","author":"Popescu","year":"2013","journal-title":"Continuum"},{"key":"10.1016\/j.ejmech.2023.115182_bib14","doi-asserted-by":"crossref","first-page":"409","DOI":"10.2174\/157015911796557911","article-title":"Multiple sclerosis: pathogenesis and treatment","volume":"9","author":"Loma","year":"2011","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.ejmech.2023.115182_bib15","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.neuron.2018.01.021","article-title":"Multiple sclerosis: mechanisms and immunotherapy","volume":"97","author":"Baecher-Allan","year":"2018","journal-title":"Neuron"},{"key":"10.1016\/j.ejmech.2023.115182_bib16","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1002\/ana.24497","article-title":"Clinical and pathological insights into the dynamic nature of the white matter multiple sclerosis plaque","volume":"78","author":"Frischer","year":"2015","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ejmech.2023.115182_bib17","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.705920","article-title":"Metabolic control of smoldering neuroinflammation","volume":"12","author":"Peruzzotti-Jametti","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejmech.2023.115182_bib18","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1002\/ana.21744","article-title":"Pathogenic CD8(+) T cells in multiple sclerosis","volume":"66","author":"Friese","year":"2009","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ejmech.2023.115182_bib19","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1517\/14728222.2013.815726","article-title":"CD8(+) T cells in multiple sclerosis","volume":"17","author":"Denic","year":"2013","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.ejmech.2023.115182_bib20","doi-asserted-by":"crossref","first-page":"239","DOI":"10.2174\/1568010053586264","article-title":"The role of CD8(+) T cells in multiple sclerosis and its animal models","volume":"4","author":"Goverman","year":"2005","journal-title":"Curr. Drug Targets - Inflamm. Allergy"},{"key":"10.1016\/j.ejmech.2023.115182_bib21","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/ana.25119","article-title":"B-Cell therapy for multiple sclerosis: entering an era","volume":"83","author":"Greenfield","year":"2018","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ejmech.2023.115182_bib22","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.msard.2018.09.025","article-title":"Leptomeningeal inflammation in multiple sclerosis: insights from animal and human studies","volume":"26","author":"Wicken","year":"2018","journal-title":"Multiple sclerosis and related disorders"},{"key":"10.1016\/j.ejmech.2023.115182_bib23","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.neurol.2018.03.012","article-title":"First-line therapy in relapsing remitting multiple sclerosis","volume":"174","author":"Biotti","year":"2018","journal-title":"Rev. Neurol."},{"key":"10.1016\/j.ejmech.2023.115182_bib24","doi-asserted-by":"crossref","first-page":"545","DOI":"10.12998\/wjcc.v3.i7.545","article-title":"Treatment strategies for multiple sclerosis: when to start, when to change, when to stop?","volume":"3","author":"Gajofatto","year":"2015","journal-title":"World J Clin Cases"},{"key":"10.1016\/j.ejmech.2023.115182_bib25","doi-asserted-by":"crossref","DOI":"10.1177\/2055217320957358","article-title":"Comparison of first-line and second-line use of fingolimod in relapsing MS: the open-label EARLIMS study","volume":"6","author":"Fern\u00e1ndez","year":"2020","journal-title":"Multiple sclerosis journal - experimental, translational and clinical"},{"key":"10.1016\/j.ejmech.2023.115182_bib26","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.msard.2018.09.041","article-title":"Effectiveness and safety of Rituximab in demyelinating diseases spectrum: an Italian experience","volume":"27","author":"D'Amico","year":"2019","journal-title":"Multiple sclerosis and related disorders"},{"key":"10.1016\/j.ejmech.2023.115182_bib27","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1056\/NEJMoa1917246","article-title":"Ofatumumab versus teriflunomide in multiple sclerosis","volume":"383","author":"Hauser","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2023.115182_bib28","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s40265-021-01650-7","article-title":"Ofatumumab: a review in relapsing forms of multiple sclerosis","volume":"82","author":"Kang","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2023.115182_bib29","doi-asserted-by":"crossref","first-page":"491","DOI":"10.2165\/11591110-000000000-00000","article-title":"The mechanism of action of interferon-\u03b2 in relapsing multiple sclerosis","volume":"25","author":"Kieseier","year":"2011","journal-title":"CNS Drugs"},{"key":"10.1016\/j.ejmech.2023.115182_bib30","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.autrev.2007.02.003","article-title":"Glatiramer acetate: mechanisms of action in multiple sclerosis","volume":"6","author":"Schrempf","year":"2007","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.ejmech.2023.115182_bib31","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s40263-021-00830-z","article-title":"Diroximel fumarate in relapsing forms of multiple sclerosis: a profile of its ucccse","volume":"35","author":"Paik","year":"2021","journal-title":"CNS Drugs"},{"key":"10.1016\/j.ejmech.2023.115182_bib32","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s00109-019-01761-5","article-title":"Insight into the mechanism of action of dimethyl fumarate in multiple sclerosis","volume":"97","author":"Yadav","year":"2019","journal-title":"J. Mol. Med."},{"key":"10.1016\/j.ejmech.2023.115182_bib33","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1177\/1352458520949158","article-title":"Progressive multifocal leukoencephalopathy in dimethyl fumarate-treated multiple sclerosis patients","volume":"28","author":"Jordan","year":"2022","journal-title":"Mult. Scler."},{"key":"10.1016\/j.ejmech.2023.115182_bib34","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1177\/1756285614546855","article-title":"Teriflunomide in the treatment of multiple sclerosis: current evidence and future prospects","volume":"7","author":"Oh","year":"2014","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.ejmech.2023.115182_bib35","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2147\/tcrm.2007.3.2.259","article-title":"Natalizumab: a new treatment for relapsing remitting multiple sclerosis","volume":"3","author":"Hutchinson","year":"2007","journal-title":"Therapeut. Clin. Risk Manag."},{"key":"10.1016\/j.ejmech.2023.115182_bib36","first-page":"50","article-title":"Reduction of the risk of PML in natalizumab treated MS patients in Sweden: an effect of improved PML risk surveillance","author":"K\u00e5gstr\u00f6m","year":"2021","journal-title":"Multiple sclerosis and related disorders"},{"key":"10.1016\/j.ejmech.2023.115182_bib37","doi-asserted-by":"crossref","first-page":"41","DOI":"10.4137\/JCNSD.S14049","article-title":"Efficacy and side effects of natalizumab therapy in patients with multiple sclerosis","volume":"6","author":"Hoepner","year":"2014","journal-title":"J. Cent. Nerv. Syst. Dis."},{"key":"10.1016\/j.ejmech.2023.115182_bib38","doi-asserted-by":"crossref","DOI":"10.1177\/1756286418773025","article-title":"Ocrelizumab: a new milestone in multiple sclerosis therapy","volume":"11","author":"Mulero","year":"2018","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.ejmech.2023.115182_bib39","first-page":"13","article-title":"Risk assessment of progressive multifocal leukoencephalopathy in multiple sclerosis patients during 1 Year of ocrelizumab treatment","author":"Prezioso","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.ejmech.2023.115182_bib40","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1001\/jamaneurol.2021.0627","article-title":"Progressive multifocal leukoencephalopathy in a patient with progressive multiple sclerosis treated with ocrelizumab monotherapy","volume":"78","author":"Patel","year":"2021","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.ejmech.2023.115182_bib41","doi-asserted-by":"crossref","first-page":"16414","DOI":"10.3390\/ijms160716414","article-title":"Alemtuzumab in multiple sclerosis: mechanism of action and beyond","volume":"16","author":"Ruck","year":"2015","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2023.115182_bib42","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s40120-022-00339-7","article-title":"Cladribine tablets for relapsing-remitting multiple sclerosis: a clinician's review","volume":"11","author":"Giovannoni","year":"2022","journal-title":"Neurology and therapy"},{"key":"10.1016\/j.ejmech.2023.115182_bib43","doi-asserted-by":"crossref","DOI":"10.1177\/11795735211069441","article-title":"Oral cladribine in patients who change from first-line disease modifying treatments for multiple sclerosis: protocol of a prospective effectiveness and safety study (CLAD CROSS)","volume":"14","author":"Tsivgoulis","year":"2022","journal-title":"J. Cent. Nerv. Syst. Dis."},{"key":"10.1016\/j.ejmech.2023.115182_bib44","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1001\/jamaneurol.2017.0676","article-title":"Interpreting lymphocyte reconstitution data from the pivotal phase 3 trials of alemtuzumab","volume":"74","author":"Baker","year":"2017","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.ejmech.2023.115182_bib45","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.743010","article-title":"Treatment with cladribine selects IFN\u03b3+IL17+ T cells in RRMS patients - an in vitro study","volume":"12","author":"Dobreanu","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejmech.2023.115182_bib46","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s40263-015-0297-0","article-title":"The direct effects of fingolimod in the central nervous system: implications for relapsing multiple sclerosis","volume":"30","author":"Hunter","year":"2016","journal-title":"CNS Drugs"},{"key":"10.1016\/j.ejmech.2023.115182_bib47","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s40265-020-01431-8","article-title":"Sphingosine 1-phosphate receptor modulator therapy for multiple sclerosis: differential downstream receptor signalling and clinical profile effects","volume":"81","author":"Chun","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2023.115182_bib48","doi-asserted-by":"crossref","first-page":"9833","DOI":"10.1074\/jbc.M412356200","article-title":"Sphingosine 1-phosphate analogs as receptor antagonists","volume":"280","author":"Davis","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2023.115182_bib49","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1146\/annurev-biochem-062411-130916","article-title":"Sphingosine-1-phosphate and its receptors: structure, signaling, and influence","volume":"82","author":"Rosen","year":"2013","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.ejmech.2023.115182_bib50","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1007\/s40265-016-0603-2","article-title":"Sphingosine-1-Phosphate (S1P) and S1P signaling pathway: therapeutic targets in autoimmunity and inflammation","volume":"76","author":"Tsai","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2023.115182_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.02.009","article-title":"Targeting the S1P receptor signaling pathways as a promising approach for treatment of autoimmune and inflammatory diseases","volume":"154","author":"Stepanovska","year":"2020","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejmech.2023.115182_bib52","series-title":"Sphingosine 1-Phosphate Receptor 1 Signaling in Mammalian Cells","first-page":"22","author":"Pyne","year":"2017"},{"key":"10.1016\/j.ejmech.2023.115182_bib53","doi-asserted-by":"crossref","DOI":"10.1111\/cmi.12836","article-title":"Sphingosine-1-phosphate receptors and innate immunity","volume":"20","author":"Bryan","year":"2018","journal-title":"Cell Microbiol."},{"key":"10.1016\/j.ejmech.2023.115182_bib54","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/S1097-2765(01)00324-0","article-title":"Akt-mediated phosphorylation of the G protein-coupled receptor EDG-1 is required for endothelial cell chemotaxis","volume":"8","author":"Lee","year":"2001","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ejmech.2023.115182_bib55","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1161\/hh0302.104455","article-title":"Sphingosine-1-phosphate, a platelet-derived lysophospholipid mediator, negatively regulates cellular Rac activity and cell migration in vascular smooth muscle cells","volume":"90","author":"Ryu","year":"2002","journal-title":"Circ. Res."},{"key":"10.1016\/j.ejmech.2023.115182_bib56","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1128\/MCB.23.5.1534-1545.2003","article-title":"Inhibitory and stimulatory regulation of Rac and cell motility by the G12\/13-Rho and Gi pathways integrated downstream of a single G protein-coupled sphingosine-1-phosphate receptor isoform","volume":"23","author":"Sugimoto","year":"2003","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.ejmech.2023.115182_bib57","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0169-328X(00)00262-X","article-title":"Differential roles of Edg-1 and Edg-5, sphingosine 1-phosphate receptors, in the signaling pathways in C6 glioma cells, Brain research","volume":"85","author":"Sato","year":"2000","journal-title":"Mol. Brain Res."},{"key":"10.1016\/j.ejmech.2023.115182_bib58","doi-asserted-by":"crossref","first-page":"8859","DOI":"10.1038\/ncomms9859","article-title":"Inhibition of SHP2-mediated dephosphorylation of Ras suppresses oncogenesis","volume":"6","author":"Bunda","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2023.115182_bib59","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.3390\/ijms18112448","article-title":"Sphingosine 1-phosphate (S1P) signaling in glioblastoma multiforme\u2014a systematic review","volume":"18","author":"Mahajan-Thakur","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2023.115182_bib60","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.4049\/jimmunol.1403168","article-title":"S1PR4 signaling attenuates ILT 7 internalization to limit IFN-\u03b1 production by human plasmacytoid dendritic cells","volume":"196","author":"Dillmann","year":"2016","journal-title":"J. Immunol."},{"key":"10.1016\/j.ejmech.2023.115182_bib61","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1038\/ni1523","article-title":"Natural killer cell trafficking in vivo requires a dedicated sphingosine 1-phosphate receptor","volume":"8","author":"Walzer","year":"2007","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.ejmech.2023.115182_bib62","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1084\/jem.20090525","article-title":"T-bet-dependent S1P5 expression in NK cells promotes egress from lymph nodes and bone marrow","volume":"206","author":"Jenne","year":"2009","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ejmech.2023.115182_bib63","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.plipres.2016.03.001","article-title":"Sphingosine 1-phosphate and sphingosine kinases in health and disease: recent advances","volume":"62","author":"Pyne","year":"2016","journal-title":"Prog. Lipid Res."},{"key":"10.1016\/j.ejmech.2023.115182_bib64","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1074\/jbc.R600028200","article-title":"Functions of the multifaceted family of sphingosine kinases and some close relatives","volume":"282","author":"Spiegel","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2023.115182_bib65","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1038\/ni1545","article-title":"Finding a way out: lymphocyte egress from lymphoid organs","volume":"8","author":"Schwab","year":"2007","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.ejmech.2023.115182_bib66","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1146\/annurev-biochem-062411-130916","article-title":"Sphingosine-1-Phosphate and its receptors: structure, signaling, and influence","volume":"82","author":"Rosen","year":"2013","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.ejmech.2023.115182_bib67","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1126\/science.1215904","article-title":"Crystal structure of a lipid G protein-coupled receptor","volume":"335","author":"Hanson","year":"2012","journal-title":"Science (New York, N.Y.)"},{"key":"10.1016\/j.ejmech.2023.115182_bib68","doi-asserted-by":"crossref","first-page":"21453","DOI":"10.1074\/jbc.C200176200","article-title":"The immune modulator FTY720 targets sphingosine 1-phosphate receptors","volume":"277","author":"Brinkmann","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2023.115182_bib69","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1080\/14656566.2018.1434143","article-title":"Potential neuroprotective effect of Fingolimod in multiple sclerosis and its association with clinical variables","volume":"19","author":"Pitteri","year":"2018","journal-title":"Expet Opin. Pharmacother."},{"key":"10.1016\/j.ejmech.2023.115182_bib70","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1056\/NEJMoa1800149","article-title":"Trial of fingolimod versus interferon beta-1a in pediatric multiple sclerosis","volume":"379","author":"Chitnis","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2023.115182_bib71","first-page":"520","article-title":"Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study, the Lancet","volume":"10","author":"Khatri","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.ejmech.2023.115182_bib72","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1056\/NEJMoa1800149","article-title":"Trial of fingolimod versus interferon beta-1a in pediatric multiple sclerosis","volume":"379","author":"Chitnis","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2023.115182_bib73","first-page":"58","article-title":"Consistent control of disease activity with fingolimod versus IFN \u03b2-1a in paediatric-onset multiple sclerosis: further insights from PARADIGMS","volume":"91","author":"Deiva","year":"2020","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.ejmech.2023.115182_bib74","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1111\/bph.13476","article-title":"Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1) and receptor-5 (S1P5) agonist with autoimmune disease-modifying activity","volume":"173","author":"Scott","year":"2016","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2023.115182_bib75","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1021\/ml300396r","article-title":"Discovery of BAF312 (siponimod), a potent and selective S1P receptor modulator","volume":"4","author":"Pan","year":"2013","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2023.115182_bib76","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1186\/s12974-016-0686-4","article-title":"Siponimod (BAF312) prevents synaptic neurodegeneration in experimental multiple sclerosis","volume":"13","author":"Gentile","year":"2016","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.ejmech.2023.115182_bib77","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s40263-022-00927-z","article-title":"The two sides of siponimod: evidence for brain and immune mechanisms in multiple sclerosis","volume":"36","author":"Cohan","year":"2022","journal-title":"CNS Drugs"},{"key":"10.1016\/j.ejmech.2023.115182_bib78","doi-asserted-by":"crossref","first-page":"e1117","DOI":"10.1212\/NXI.0000000000001117","article-title":"Siponimod inhibits the formation of meningeal ectopic lymphoid tissue in experimental autoimmune encephalomyelitis","volume":"9","author":"Brand","year":"2022","journal-title":"Neurology - Neuroimmunology Neuroinflammation"},{"key":"10.1016\/j.ejmech.2023.115182_bib79","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/S0140-6736(18)30475-6","article-title":"Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study","volume":"391","author":"Kappos","year":"2018","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.ejmech.2023.115182_bib80","first-page":"756","article-title":"Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study, the Lancet","volume":"12","author":"Selmaj","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.ejmech.2023.115182_bib81","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.2147\/DDDT.S122249","article-title":"Spotlight on siponimod and its potential in the treatment of secondary progressive multiple sclerosis: the evidence to date","volume":"11","author":"Gajofatto","year":"2017","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.ejmech.2023.115182_bib82","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1002\/ejoc.202100058","article-title":"Enantioselective synthesis of ozanimod, the active pharmaceutical ingredient of a new drug for multiple sclerosis","volume":"2021","author":"Cianferotti","year":"2021","journal-title":"Eur. J. Org Chem."},{"key":"10.1016\/j.ejmech.2023.115182_bib83","first-page":"1021","article-title":"Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial, the Lancet","volume":"18","author":"Cohen","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.ejmech.2023.115182_bib84","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102844","article-title":"Ozanimod in relapsing multiple sclerosis: pooled safety results from the clinical development program","volume":"51","author":"Selmaj","year":"2021","journal-title":"Multiple sclerosis and related disorders"},{"key":"10.1016\/j.ejmech.2023.115182_bib85","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/cpdd.383","article-title":"Cardiac safety of ozanimod, a novel sphingosine-1-phosphate receptor modulator: results of a thorough QT\/QTc study","volume":"7","author":"Tran","year":"2018","journal-title":"Clinical pharmacology in drug development"},{"key":"10.1016\/j.ejmech.2023.115182_bib86","doi-asserted-by":"crossref","first-page":"4198","DOI":"10.1021\/jm100181s","article-title":"2-imino-thiazolidin-4-one derivatives as potent, orally active S1P1 receptor agonists","volume":"53","author":"Bolli","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115182_bib87","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1136\/jnnp-2013-307282","article-title":"Oral ponesimod in relapsing-remitting multiple sclerosis: a randomised phase II trial","volume":"85","author":"Olsson","year":"2014","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.ejmech.2023.115182_bib88","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1001\/jamaneurol.2021.0405","article-title":"Ponesimod compared with teriflunomide in patients with relapsing multiple sclerosis in the active-comparator phase 3 optimum study: a randomized clinical trial","volume":"78","author":"Kappos","year":"2021","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.ejmech.2023.115182_bib89","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/ana.22366","article-title":"Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria","volume":"69","author":"Polman","year":"2011","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ejmech.2023.115182_bib90","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1001\/jamaneurol.2021.0405","article-title":"Ponesimod compared with teriflunomide in patients with relapsing multiple sclerosis in the active-comparator phase 3 optimum study: a randomized clinical trial","volume":"78","author":"Kappos","year":"2021","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.ejmech.2023.115182_bib91","first-page":"61","article-title":"Ponesimod in the treatment of relapsing forms of multiple sclerosis: an update on the emerging clinical data","volume":"12","author":"Ruggieri","year":"2022","journal-title":"Degener. Neurol. Neuromuscul. Dis."},{"key":"10.1016\/j.ejmech.2023.115182_bib92","doi-asserted-by":"crossref","first-page":"9508","DOI":"10.1021\/acs.jmedchem.7b00785","article-title":"Discovery of a 1-Methyl-3,4-dihydronaphthalene-Based sphingosine-1-phosphate (S1P) receptor agonist ceralifimod (ONO-4641). A S1P1 and S1P5 selective agonist for the treatment of autoimmune diseases","volume":"60","author":"Kurata","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115182_bib93","volume":"80","author":"Selmaj","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.ejmech.2023.115182_bib94","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.82.10_supplement.P3.161","article-title":"Effect of ceralifimod (ONO-4641), a sphingosine-1-phosphate receptor-1 and -5 agonist, on magnetic resonance imaging outcomes in patients with multiple sclerosis: interim results from the extension of the DreaMS study (P3.161)","volume":"82","author":"Bar-Or","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.ejmech.2023.115182_bib95","first-page":"170","article-title":"Safety, pharmacokinetics, pharmacodynamics, and bioavailability of GSK2018682, a sphingosine-1-phosphate receptor modulator","volume":"3","author":"Xu","year":"2014"},{"key":"10.1016\/j.ejmech.2023.115182_bib96","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/bph.13641","article-title":"Amiselimod, a novel sphingosine 1-phosphate receptor-1 modulator, has potent therapeutic efficacy for autoimmune diseases, with low bradycardia risk","volume":"174","author":"Sugahara","year":"2017","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2023.115182_bib97","first-page":"1148","article-title":"Safety and efficacy of amiselimod in relapsing multiple sclerosis (MOMENTUM): a randomised, double-blind, placebo-controlled phase 2 trial, the Lancet","volume":"15","author":"Kappos","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.ejmech.2023.115182_bib98","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1111\/bcp.13203","article-title":"Cardiac effects of amiselimod compared with fingolimod and placebo: results of a randomised, parallel-group, phase I study in healthy subjects","volume":"83","author":"Harada","year":"2017","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejmech.2023.115182_bib99","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1177\/1352458517728343","article-title":"Two-year results from a phase 2 extension study of oral amiselimod in relapsing multiple sclerosis","volume":"24","author":"Kappos","year":"2018","journal-title":"Mult. Scler."},{"key":"10.1016\/j.ejmech.2023.115182_bib100","doi-asserted-by":"crossref","first-page":"9833","DOI":"10.1074\/jbc.M412356200","article-title":"Sphingosine 1-phosphate analogs as receptor antagonists","volume":"280","author":"Davis","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2023.115182_bib101","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1124\/mol.108.049783","article-title":"Full pharmacological efficacy of a novel S1P1 agonist that does not require S1P-like headgroup interactions","volume":"74","author":"Gonzalez-Cabrera","year":"2008","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ejmech.2023.115182_bib102","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0110819","article-title":"ASP4058, a novel agonist for sphingosine 1-phosphate receptors 1 and 5, ameliorates rodent experimental autoimmune encephalomyelitis with a favorable safety profile","volume":"9","author":"Yamamoto","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2023.115182_bib103","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/nchembio.547","article-title":"Actions of a picomolar short-acting S1P\u2081 agonist in S1P\u2081-eGFP knock-in mice","volume":"7","author":"Cahalan","year":"2011","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2023.115182_bib104","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1021\/ml500389m","article-title":"Discovery of APD334: design of a clinical stage functional antagonist of the sphingosine-1-phosphate-1 receptor","volume":"5","author":"Buzard","year":"2014","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2023.115182_bib105","series-title":"Cenerimod, a Novel Selective S1P(1) Receptor Modulator with Unique Signaling Properties","first-page":"5","author":"Piali","year":"2017"},{"key":"10.1016\/j.ejmech.2023.115182_bib106","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1021\/acs.jmedchem.5b01512","article-title":"Discovery of tetrahydropyrazolopyridine as sphingosine 1-phosphate receptor 3 (S1P3)-sparing S1P1 agonists active at low oral doses","volume":"59","author":"Demont","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115182_bib107","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2117716119","article-title":"Structural insights into sphingosine-1-phosphate receptor activation","volume":"119","author":"Yu","year":"2022","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ejmech.2023.115182_bib108","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/s41589-021-00930-3","article-title":"Structural basis of sphingosine-1-phosphate receptor 1 activation and biased agonism","volume":"18","author":"Xu","year":"2022","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2023.115182_bib109","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aax8050","article-title":"A G protein-biased S1P(1) agonist, SAR247799, protects endothelial cells without affecting lymphocyte numbers","volume":"13","author":"Poirier","year":"2020","journal-title":"Sci. Signal."},{"key":"10.1016\/j.ejmech.2023.115182_bib110","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1021\/acs.jmedchem.0c01109","article-title":"Bicyclic ligand-biased agonists of S1P(1): exploring side chain modifications to modulate the PK, PD, and safety profiles","volume":"64","author":"Gilmore","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115182_bib111","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.1021\/jm000941m","article-title":"GRid-INdependent descriptors (GRIND): a novel class of alignment-independent three-dimensional molecular descriptors","volume":"43","author":"Pastor","year":"2000","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115182_bib112","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.ejmech.2013.06.048","article-title":"3D-QSAR using pharmacophore-based alignment and virtual screening for discovery of novel MCF-7 cell line inhibitors","volume":"67","author":"Brogi","year":"2013","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115182_bib113","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0204378","article-title":"2nd, the integration of pharmacophore-based 3D QSAR modeling and virtual screening in safety profiling: a case study to identify antagonistic activities against adenosine receptor, A2A, using 1,897 known drugs","volume":"14","author":"Fan","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2023.115182_bib114","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2018.01275","article-title":"QSAR-based virtual screening: advances and applications in drug discovery","volume":"9","author":"Neves","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2023.115182_bib115","first-page":"113","article-title":"Drug repurposing for identification of S1P1 agonists with potential application in multiple sclerosis using in silico drug design approaches","volume":"13","author":"Alizadeh","year":"2023","journal-title":"Adv. Pharmaceut. Bull."},{"key":"10.1016\/j.ejmech.2023.115182_bib116","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmgm.2019.107459","article-title":"Alignment independent 3D-QSAR studies and molecular dynamics simulations for the identification of potent and selective S1P(1) receptor agonists","volume":"94","author":"Alizadeh","year":"2020","journal-title":"J. Mol. Graph. Model."},{"key":"10.1016\/j.ejmech.2023.115182_bib117","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1007\/s13738-018-1440-x","article-title":"Computational explorations to gain insight into the structural features of TNF-\u03b1 receptor I inhibitors","volume":"15","author":"Sharifi","year":"2018","journal-title":"J. Iran. Chem. Soc."},{"key":"10.1016\/j.ejmech.2023.115182_bib118","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1002\/prot.10465","article-title":"Improved protein-ligand docking using GOLD","volume":"52","author":"Verdonk","year":"2003","journal-title":"Proteins"},{"key":"10.1016\/j.ejmech.2023.115182_bib119","first-page":"689","article-title":"Oral fingolimod for chronic inflammatory demyelinating polyradiculoneuropathy (FORCIDP Trial): a double-blind, multicentre, randomised controlled trial, the Lancet","volume":"17","author":"Hughes","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.ejmech.2023.115182_bib120","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1093\/ecco-jcc\/jjab012","article-title":"Long-term efficacy and safety of ozanimod in moderately to severely active ulcerative colitis: results from the open-label extension of the randomized, phase 2 TOUCHSTONE study","volume":"15","author":"Sandborn","year":"2021","journal-title":"Journal of Crohn's & colitis"},{"key":"10.1016\/j.ejmech.2023.115182_bib121","first-page":"819","article-title":"Ozanimod induction therapy for patients with moderate to severe Crohn's disease: a single-arm, phase 2, prospective observer-blinded endpoint study, the lancet","volume":"5","author":"Feagan","year":"2020","journal-title":"Gastroenterol. Hepatol."},{"key":"10.1016\/j.ejmech.2023.115182_bib122","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1056\/NEJMoa2033617","article-title":"Ozanimod as induction and maintenance therapy for ulcerative colitis","volume":"385","author":"Sandborn","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2023.115182_bib123","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1053\/j.gastro.2019.10.035","article-title":"Efficacy and safety of etrasimod in a phase 2 randomized trial of patients with ulcerative colitis","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejmech.2023.115182_bib124","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.chembiol.2012.07.016","article-title":"A potent and selective S1P(1) antagonist with efficacy in experimental autoimmune encephalomyelitis","volume":"19","author":"Quancard","year":"2012","journal-title":"Chem. Biol."},{"key":"10.1016\/j.ejmech.2023.115182_bib125","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1124\/jpet.111.181552","article-title":"Characterization of a sphingosine 1-phosphate receptor antagonist prodrug","volume":"338","author":"Kennedy","year":"2011","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejmech.2023.115182_bib126","doi-asserted-by":"crossref","first-page":"23940","DOI":"10.1074\/jbc.274.34.23940","article-title":"Comparison of intrinsic activities of the putative sphingosine 1-phosphate receptor subtypes to regulate several signaling pathways in their cDNA-transfected Chinese hamster ovary cells","volume":"274","author":"Kon","year":"1999","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2023.115182_bib127","doi-asserted-by":"crossref","first-page":"49213","DOI":"10.1074\/jbc.M107301200","article-title":"A single amino acid determines lysophospholipid specificity of the S1P1 (EDG1) and LPA1 (EDG2) phospholipid growth factor receptors","volume":"276","author":"Wang","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2023.115182_bib128","doi-asserted-by":"crossref","first-page":"13839","DOI":"10.1074\/jbc.M311743200","article-title":"Sphingosine 1-phosphate (S1P) receptor subtypes S1P1 and S1P3, respectively, regulate lymphocyte recirculation and heart rate","volume":"279","author":"Sanna","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2023.115182_bib129","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1177\/1352458518789884","article-title":"Efficacy and safety of ozanimod in multiple sclerosis: dose-blinded extension of a randomized phase II study","volume":"25","author":"Cohen","year":"2019","journal-title":"Mult. Scler."},{"key":"10.1016\/j.ejmech.2023.115182_bib130","first-page":"10935","article-title":"The selective sphingosine 1-phosphate receptor 1 modulator RP101075 improves microvascular circulation after cerebrovascular thrombosis","volume":"33","author":"Li","year":"2019","journal-title":"Faseb. J. off. pub. Fed. Am. Soc. Exp. Biol."},{"key":"10.1016\/j.ejmech.2023.115182_bib131","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1007\/s40262-021-01020-2","article-title":"An exposure-response analysis of the clinical efficacy of ponesimod in a randomized phase II study in patients with multiple sclerosis","volume":"60","author":"Gisleskog","year":"2021","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejmech.2023.115182_bib132","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1016\/S0140-6736(14)60803-5","article-title":"Oral ponesimod in patients with chronic plaque psoriasis: a randomised, double-blind, placebo-controlled phase 2 trial","volume":"384","author":"Vaclavkova","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2023.115182_bib133","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1159\/000509393","article-title":"A multicentre, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety, and tolerability of the S1P receptor agonist KRP203 in patients with moderately active refractory ulcerative colitis","volume":"5","author":"Radeke","year":"2020","journal-title":"Inflammatory Intestinal Diseases"},{"key":"10.1016\/j.ejmech.2023.115182_bib134","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jneuroim.2009.09.010","article-title":"AUY954, a selective S1P1 modulator, prevents experimental autoimmune neuritis","volume":"216","author":"Zhang","year":"2009","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.ejmech.2023.115182_bib135","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2019-000354","article-title":"First use of cenerimod, a selective S1P(1) receptor modulator, for the treatment of SLE: a double-blind, randomised, placebo-controlled, proof-of-concept study","volume":"6","author":"Hermann","year":"2019","journal-title":"Lupus science & medicine"},{"key":"10.1016\/j.ejmech.2023.115182_bib136","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1038\/cmi.2014.59","article-title":"The S1P1 receptor-selective agonist CYM-5442 reduces the severity of acute GVHD by inhibiting macrophage recruitment","volume":"12","author":"Cheng","year":"2015","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.ejmech.2023.115182_bib137","doi-asserted-by":"crossref","first-page":"6169","DOI":"10.1021\/jm0503244","article-title":"Discovery of potent 3,5-Diphenyl-1,2,4-oxadiazole sphingosine-1-phosphate-1 (S1P1) receptor agonists with exceptional selectivity against S1P2 and S1P3","volume":"48","author":"Li","year":"2005","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115182_bib138","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1111\/bph.13820","article-title":"A sphingosine-1-phosphate receptor type 1 agonist, ASP4058, suppresses intracranial aneurysm through promoting endothelial integrity and blocking macrophage transmigration","volume":"174","author":"Yamamoto","year":"2017","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2023.115182_bib139","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1093\/hmg\/ddy153","article-title":"Stimulation of S1PR5 with A-971432, a selective agonist, preserves blood\u2013brain barrier integrity and exerts therapeutic effect in an animal model of Huntington's disease","volume":"27","author":"Di Pardo","year":"2018","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ejmech.2023.115182_bib140","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1056\/NEJMoa0909494","article-title":"A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis","volume":"362","author":"Kappos","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2023.115182_bib141","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13023-020-01655-7","article-title":"Fingolimod in children with Rett syndrome: the FINGORETT study","volume":"16","author":"Naegelin","year":"2021","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ejmech.2023.115182_bib142","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1365-2249.2012.04669.x","article-title":"Efficacy and immunomodulatory actions of ONO-4641, a novel selective agonist for sphingosine 1-phosphate receptors 1 and 5, in preclinical models of multiple sclerosis","volume":"171","author":"Komiya","year":"2013","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.ejmech.2023.115182_bib143","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nature04753","article-title":"Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells","volume":"441","author":"Bettelli","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2023.115182_bib144","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1172\/JCI63681","article-title":"IL-17A secretion by CD8+ T cells supports Th17-mediated autoimmune encephalomyelitis","volume":"123","author":"Huber","year":"2013","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ejmech.2023.115182_bib145","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/nri819","article-title":"Cytotoxic T lymphocytes: all roads lead to death","volume":"2","author":"Barry","year":"2002","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ejmech.2023.115182_bib146","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.bbi.2010.01.014","article-title":"Infiltration of Th1 and Th17 cells and activation of microglia in the CNS during the course of experimental autoimmune encephalomyelitis","volume":"24","author":"Murphy","year":"2010","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.ejmech.2023.115182_bib147","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0135434","article-title":"Immune parameters that distinguish multiple sclerosis patients from patients with other neurological disorders at presentation","volume":"10","author":"Mouzaki","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2023.115182_bib148","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.phrs.2007.11.003","article-title":"Role of natural killer cells in the pathogenesis and progression of multiple sclerosis","volume":"57","author":"Morandi","year":"2008","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejmech.2023.115182_bib149","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s10072-007-0803-3","article-title":"Expansion of CD56Bright natural killer cells in the peripheral blood of multiple sclerosis patients treated with interferon-beta","volume":"28","author":"Saraste","year":"2007","journal-title":"Neurol. Sci. off.: j. Ital. Neurol. Soc. Italian Soc. Clin. Neurophysiol."},{"key":"10.1016\/j.ejmech.2023.115182_bib150","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1093\/brain\/awm038","article-title":"Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology","volume":"130","author":"Magliozzi","year":"2007","journal-title":"Brain: J. Neurol."},{"key":"10.1016\/j.ejmech.2023.115182_bib151","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/j.1750-3639.2004.tb00049.x","article-title":"Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis","volume":"14","author":"Serafini","year":"2004","journal-title":"Brain Pathol."},{"key":"10.1016\/j.ejmech.2023.115182_bib152","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1084\/jem.20130699","article-title":"MHC class II-dependent B cell APC function is required for induction of CNS autoimmunity independent of myelin-specific antibodies","volume":"210","author":"Molnarfi","year":"2013","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ejmech.2023.115182_bib153","doi-asserted-by":"crossref","first-page":"27351","DOI":"10.1074\/jbc.274.39.27351","article-title":"Differential coupling of the sphingosine 1-phosphate receptors Edg-1, Edg-3, and H218\/Edg-5 to the G(i), G(q), and G(12) families of heterotrimeric G proteins","volume":"274","author":"Windh","year":"1999","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2023.115182_bib154","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1042\/bj20020867","article-title":"Assessment of the role of sphingosine 1-phosphate and its receptors in high-density lipoprotein-induced stimulation of astroglial cell function","volume":"370","author":"Malchinkhuu","year":"2003","journal-title":"Biochem. J."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523423000971?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523423000971?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:47:19Z","timestamp":1759330039000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523423000971"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":154,"alternative-id":["S0223523423000971"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2023.115182","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"S1PR1 modulators in multiple sclerosis: Efficacy, safety, comparison, and chemical structure insights","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2023.115182","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115182"}}